About BrainGate

BrainGate™ is a transformative neurotechnology owned and operated by Tufts University that uses micro-electrodes implanted in the brain to let humans operate external devices such as computers or robotic arms with just their thought. Through years of advanced research, BrainGate™ is at the forefront of enabling severely motor-impaired individuals with the ability to communicate, interact, and function through thought. BrainGate™ is the only technology with an FDA-approved investigational device exemption to conduct human trials of brain-computer interface (BCI) technologies.

Today, BrainGate™ is used to create technology that will allow severely disabled individuals—including those with traumatic spinal cord injury and loss of limbs—to communicate and control common every-day functions literally through thought. BrainGate, Inc.’s mission is to improve of the quality of life for all disabled humans as well as to increase the usage of BrainGate™ related technology in both medical and non-medical applications as a means to facilitate innovation in invasive and non-invasive brain research.

BrainGate, Inc. is focused on the advancement of the BrainGate™ Neural Interface System. BrainGate, Inc. owns the intellectual property of Cyberkinetics, as well as the intellectual property of the BrainGate™ system and any new technology further developed on the system by the company.

BrainGate, Inc. was founded by Jeffrey M. Stibel and a seasoned team of entrepreneurs with the hope to advance movement through thought alone. This was achieved alongside leading academic institutions, corporations, and various non-profit and government organizations working on the research, science, and development of applied commercial technology. In 2019, BrainGate™ and its core technology was donated to Tufts University as part of a larger grant to facilitate further research and practical applications.

Learn more about BrainGate™ research and development at Tufts:

BrainGate’s Intellectual Property

BrainGate™ has a strong and diverse intellectual property portfolio, including exclusive rights to key patents surrounding neural interfaces and their use to control computers, prosthesis, and other devices.

In addition to its unique patent portfolio, BrainGate™ is also focused on the analysis and interpretation of neural recordings through software and neural network innovation. In the future, this capability could allow for the recording of electrical data for future analysis, a massive advantage for medical practitioners to study patients’ everyday patterns to determine medical treatment. For example, a potential use of this feature would be for a neurologist to study seizure patterns in a patient with epilepsy.

Explore a sample of BrainGate’s™ current patent portfolio here:

BrainGate’s Trademarks

BrainGate, Cyberkinetics, Neuroport, Cerebus, Bionics, and “Turning Thoughts into Action” are trademarks of BrainGate, Co. in the U.S. and other countries.